In the past week, AKRO stock has gone down by -6.05%, with a monthly decline of -24.74% and a quarterly surge of 3.42%. The volatility ratio for the week is 5.28%, and the volatility levels for the last 30 days are 7.10% for Akero Therapeutics Inc The simple moving average for the last 20 days is -13.41% for AKRO’s stock, with a simple moving average of -25.96% for the last 200 days.
Is It Worth Investing in Akero Therapeutics Inc (NASDAQ: AKRO) Right Now?
AKRO has 36-month beta value of -0.37. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AKRO is 57.62M, and currently, short sellers hold a 16.44% ratio of that float. The average trading volume of AKRO on April 05, 2024 was 1.40M shares.
AKRO) stock’s latest price update
Akero Therapeutics Inc (NASDAQ: AKRO)’s stock price has gone decline by -0.91 in comparison to its previous close of 23.18, however, the company has experienced a -6.05% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-05 that Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.
Analysts’ Opinion of AKRO
Many brokerage firms have already submitted their reports for AKRO stocks, with Cantor Fitzgerald repeating the rating for AKRO by listing it as a “Overweight.” The predicted price for AKRO in the upcoming period, according to Cantor Fitzgerald is $69 based on the research report published on September 19, 2023 of the previous year 2023.
UBS, on the other hand, stated in their research note that they expect to see AKRO reach a price target of $83. The rating they have provided for AKRO stocks is “Buy” according to the report published on August 28th, 2023.
Morgan Stanley gave a rating of “Overweight” to AKRO, setting the target price at $65 in the report published on January 27th of the previous year.
AKRO Trading at -5.79% from the 50-Day Moving Average
After a stumble in the market that brought AKRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.65% of loss for the given period.
Volatility was left at 7.10%, however, over the last 30 days, the volatility rate increased by 5.28%, as shares sank -23.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.45% upper at present.
During the last 5 trading sessions, AKRO fell by -6.05%, which changed the moving average for the period of 200-days by -57.93% in comparison to the 20-day moving average, which settled at $26.18. In addition, Akero Therapeutics Inc saw -1.63% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKRO starting from Young Jonathan, who sale 5,000 shares at the price of $24.38 back on Apr 01 ’24. After this action, Young Jonathan now owns 263,306 shares of Akero Therapeutics Inc, valued at $121,913 using the latest closing price.
Cheng Andrew, the President and CEO of Akero Therapeutics Inc, sale 1,969 shares at $28.33 during a trade that took place back on Mar 13 ’24, which means that Cheng Andrew is holding 589,447 shares at $55,782 based on the most recent closing price.
Stock Fundamentals for AKRO
Current profitability levels for the company are sitting at:
- -608.7 for the present operating margin
- 0.49 for the gross margin
The net margin for Akero Therapeutics Inc stands at -525.68. The total capital return value is set at -0.31. Equity return is now at value -35.22, with -32.40 for asset returns.
Based on Akero Therapeutics Inc (AKRO), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -5.76. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -55.78.
Currently, EBITDA for the company is -172.84 million with net debt to EBITDA at 1.33. When we switch over and look at the enterprise to sales, we see a ratio of 4843.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 29.27.
Conclusion
To put it simply, Akero Therapeutics Inc (AKRO) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
